Judith Karp

Professor Emeritus

1974 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Judith Karp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
alvocidib Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
tipifarnib Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1974 2018

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

Litzow, M. R., Wang, X. V., Carroll, M. P., Karp, J., Ketterling, R. P., Zhang, Y., Kaufmann, S. H., Lazarus, H. M., Luger, S. M., Paietta, E. M., Pratz, K., Tun, H. W., Altman, J. K., Broun, E. R., Rybka, W. B., Rowe, J. M. & Tallman, M. S., Jan 1 2018, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

alvocidib
Mitoxantrone
Cytarabine
Acute Myeloid Leukemia
Topotecan

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C., Rosner, G., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

on behalf of the ETCTN-6745 study team, Jan 1 2018, (Accepted/In press) In : Cancer Chemotherapy and Pharmacology.

Research output: Contribution to journalArticle

temozolomide
Myeloid Leukemia
Pharmacokinetics
Population
Mucositis

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

Knaus, H. A., Berglund, S., Hackl, H., Blackford, A. L., Zeidner, J. F., Montiel-Esparza, R., Mukhopadhyay, R., Vanura, K., Blazar, B. R., Karp, J., Luznik, L. & Gojo, I., Nov 2 2018, In : JCI insight. 3, 21

Research output: Contribution to journalArticle

Open Access
Acute Myeloid Leukemia
T-Lymphocytes
Drug Therapy
Induction Chemotherapy
Immunity

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I., Beumer, J. H., Pratz, K., McDevitt, M. A., Baer, M. R., Blackford, A. L., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M., Levis, M. J., Dezern, A., Gladstone, D., Ji, J. J., Wang, L., Kinders, R. J., Pouquet, M., Ali-Walbi, I., Rudek-Renaut, M., Poh, W. & 5 others, Herman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J., Feb 1 2017, In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

temozolomide
Acute Myeloid Leukemia
Methylation
Phosphorylation
Polymers